Atypical Hemolytic-Uremic Syndrome: Genetic Basis, Clinical Manifestations, and a Multidisciplinary Approach to Management

References

• Loirat C, Fakhouri F, Ariceta G, et al. HUS International. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016;31(1):15–39. doi:10.1007/s00467-015-3076-8
   PubMed Web of Science ®Google Scholar
• Afshar-Kharghan V. Atypical hemolytic uremic syndrome. Hematol Am Soc Hematol Educ Prog. 2016;2016(1):217–225. doi:10.1182/asheducation-2016.1.217
   PubMedGoogle Scholar
• Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361(17):1676–1687. doi:10.1056/NEJMra0902814
   PubMed Web of Science ®Google Scholar
• Janeway CA, Travers P, Walport M, et al. Immunobiology: the immune system in health and disease. In: The Complement System and Innate Immunity. 5th ed. New York: Garland Science;2001. Available from: www.ncbi.nlm.nih.gov/books/NBK27100/.
   Google Scholar
• Morgan BP. The complement system: an overview. Methods Mol Biol. 2000;150:1–13. doi:10.1385/1-59259-056-X:1
   PubMedGoogle Scholar
• Barnum SR, Bubeck D, Schein TN. Soluble membrane attack complex: biochemistry and immunobiology. Front Immunol. 2020;11:585108. doi:10.3389/fimmu.2020.585108
   PubMed Web of Science ®Google Scholar
• Caprioli J, Noris M, Brioschi S, et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006;108(4):1267–1279. doi:10.1182/blood-2005-10-007252
   PubMed Web of Science ®Google Scholar
• Yan K, Desai K, Gullapalli L, Druyts E, Balijepalli C. Epidemiology of atypical hemolytic uremic syndrome: a systematic literature review. Clin Epidemiol. 2020;12:295–305. doi:10.2147/CLEP.S245642
   PubMed Web of Science ®Google Scholar
• Parente R, Clark SJ, Inforzato A, Day AJ. Complement factor H in host defense and immune evasion. Cell Mol Life Sci. 2017;74(9):1605–1624. doi:10.1007/s00018-016-2418-4
   PubMed Web of Science ®Google Scholar
• Pangburn MK. Host recognition and target differentiation by factor H, a regulator of the alternative pathway of complement. Immunopharmacology. 2000;49(1–2):149–157. doi:10.1016/S0162-3109(00)80300-8
   PubMedGoogle Scholar
• Bernabeu-Herrero ME, Jimenez-Alcazar M, Anter J, et al. Complement factor H, FHR-3 and FHR-1 variants associate in an extended haplotype conferring increased risk of atypical hemolytic uremic syndrome. Mol Immunol. 2015;67(2 pt B):276–286. doi:10.1016/j.molimm.2015.06.021
   PubMed Web of Science ®Google Scholar
• Skerka C, Chen Q, Fremeaux-Bacchi V, Roumenina LT. Complement factor H related proteins (CFHRs). Mol Immunol. 2013;56(3):170–180. doi:10.1016/j.molimm.2013.06.001
   PubMed Web of Science ®Google Scholar
• Dragon-Durey MA, Loirat C, Cloarec S, et al. Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2005;16:555–563. doi:10.1681/ASN.2004050380
   PubMed Web of Science ®Google Scholar
• Lachmann PJ. The amplification loop of the complement pathways. Adv Immunol. 2009;104:115–149.
   PubMed Web of Science ®Google Scholar
• Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J, et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci USA. 2007;104:240–245. doi:10.1073/pnas.0603420103
   PubMed Web of Science ®Google Scholar
• Fremeaux-Bacchi V, Miller EC, Liszewski MK, et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood. 2008;112:4948–4952. doi:10.1182/blood-2008-01-133702
   PubMed Web of Science ®Google Scholar
• Loirat C, Fremeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis. 2011;6:60. doi:10.1186/1750-1172-6-60
   PubMed Web of Science ®Google Scholar
• Nester CM, Barbour T, de Cordoba SR, et al. Atypical aHUS: state of the art. Mol Immunol. 2015;67(1):31–42. doi:10.1016/j.molimm.2015.03.246
   PubMed Web of Science ®Google Scholar
• Nester CM, Thomas CP. Atypical hemolytic uremic syndrome: what is it, how is it diagnosed, and how is it treated? Hematol Am Soc Hematol Educ Prog. 2012;2012:617–625. doi:10.1182/asheducation-2012.1.617
   PubMedGoogle Scholar
• Mohammed SK, Mubarik A, Nadeem B, et al. Atypical hemolytic uremic syndrome: a case report. Cureus. 2019;11(5):e4634. doi:10.7759/cureus.4634
   PubMed Web of Science ®Google Scholar
• Wu H, Su S, Li L, Zhang L. Atypical hemolytic uremic syndrome and acute tubular necrosis induced by complement factor B gene (CFB) mutation: a case report. Medicine. 2021;100:e25069.
   PubMed Web of Science ®Google Scholar
• Basnayake B, Wazil AWM, Nanayakkara N, et al. Atypical hemolytic uremic syndrome: a case report. J Med Case Rep. 2020;14(11). doi:10.1186/s13256-019-2334-y
   PubMedGoogle Scholar
• Krishnappa V, Gupta M, Elrifai M, et al. Atypical hemolytic uremic syndrome: a meta-analysis of case reports confirms the prevalence of genetic mutations and the shift of treatment regimens. Ther Apher Dial. 2018;22(2):178–188. doi:10.1111/1744-9987.12641
   PubMed Web of Science ®Google Scholar
• Jamme M, Raimbourg Q, Chauveau D, et al; French Thrombotic Microangiopathies Reference Centre. Predictive features of chronic kidney disease in atypical haemolytic uremic syndrome. PLoS One. 2017;12(5):e0177894. doi:10.1371/journal.pone.0177894
   PubMed Web of Science ®Google Scholar
• Sallée M, Daniel L, Piercecchi MD, et al. Myocardial infarction is a complication of factor H-associated atypical HUS. Nephrol Dial Transplant. 2010;25(6):2028–2032. doi:10.1093/ndt/gfq160
   PubMed Web of Science ®Google Scholar
• Vilalta R, Lara E, Madrid A, et al. Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome. Pediatr Nephrol. 2012;27(12):2323–2326. doi:10.1007/s00467-012-2276-8
   PubMed Web of Science ®Google Scholar
• Loirat C, Macher MA, Elmaleh-Berges M, et al. Non-atheromatous arterial stenoses in atypical haemolytic uraemic syndrome associated with complement dysregulation. Nephrol Dial Transplant. 2010;25(10):3421–3425. doi:10.1093/ndt/gfq319
   PubMed Web of Science ®Google Scholar
• Gomez-Lado C, Martinon-Torres F, Alvarez-Moreno A, et al. Reversible posterior leukoencephalopathy syndrome: an infrequent complication in the course of haemolytic-uremic syndrome. Rev Neurol. 2007;44(8):475–478.
   PubMed Web of Science ®Google Scholar
• Koehl B, Boyer O, Biebuyck-Gouge N, et al. Neurological involvement in a child with atypical hemolytic uremic syndrome. Pediatr Nephrol. 2010;25(12):2539–2542. doi:10.1007/s00467010-1606-y
   PubMed Web of Science ®Google Scholar
• Ažukaitis K, Loirat C, Malina M, et al. Macrovascular involvement in a child with atypical hemolytic uremic syndrome. Pediatr Nephrol. 2013;29:1273–1277. doi:10.1007/s00467-013-2713-3
   PubMed Web of Science ®Google Scholar
• Malina M, Gulati A, Bagga A, Majid MA, Simkova E, Schaefer F. Peripheral gangrene in children with atypical hemolytic uremic syndrome. Pediatrics. 2013;131(1):e331–5. doi:10.1542/peds.2012-0903
   PubMed Web of Science ®Google Scholar
• Roman-Ortiz E, Mendizabal Oteiza S, Pinto S, Lopez-Trascasa M, Sanchez-Corral P, Rodriguez de Cordoba S. Eculizumab long-term therapy for pediatric renal transplant in aHUS with CFH/CFHR1 hybrid gene. Pediatr Nephrol. 2014;29:149–153. doi:10.1007/s00467-013-2591-8
   PubMed Web of Science ®Google Scholar
• Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, et al; French Society of Pediatric Network. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2007;18:2392–2400. doi:10.1681/ASN.2006080811
   PubMed Web of Science ®Google Scholar
• Dragon-Durey MA, Sethi SK, Bagga A, et al. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol. 2010;21:2180–2187. doi:10.1681/ASN.2010030315
   PubMed Web of Science ®Google Scholar
• Formeck C, Swiatecka-Urban A. Extra-renal manifestations of atypical hemolytic uremic syndrome. Pediatr Nephrol. 2019;34:1337–1348. doi:10.1007/s00467-018-4039-7
   PubMed Web of Science ®Google Scholar
• Berger BE. The alternative pathway of complement and the evolving clinical-pathophysiological spectrum of atypical hemolytic uremic syndrome. Am J Med Sci. 2016;352:177–190. doi:10.1016/j.amjms.2016.05.003
   PubMed Web of Science ®Google Scholar
• Brocklebank V, Johnson S, Sheerin TP, et al. Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland. Kidney Int. 2017;92:1261–1271. doi:10.1016/j.kint.2017.04.028
   PubMed Web of Science ®Google Scholar
• Besbas N, Gulhan B, Soylemezoglu O, et al. Turkish pediatric atypical hemolytic uremic syndrome registry: initial analysis of 146 patients. BMC Nephrol. 2017;18:6. doi:10.1186/s12882-016-0420-6
   PubMed Web of Science ®Google Scholar
• Webb TN, Griffiths H, Miyashita Y, et al. Atypical hemolytic uremic syndrome and chronic ulcerative colitis treated with eculizumab. Int J Med Pharm Case Rep. 2015;4(5):105–112. doi:10.9734/IJMPCR/2015/18771
   PubMedGoogle Scholar
• Green H, Harari E, Davidovits M, et al. Atypical HUS due to factor H antibodies in an adult patient successfully treated with eculizumab. Ren Fail. 2014;36(7):1119–1121. doi:10.3109/0886022X.2014.917574
   PubMed Web of Science ®Google Scholar
• Fakhouri F, Roumenina L, Provot F, et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol. 2010;21(5):859–867. doi:10.1681/ASN.2009070706
   PubMed Web of Science ®Google Scholar
• Meibody F, Jamme M, Tsatsaris V, et al. Post-partum acute kidney injury: sorting placental and non-placental thrombotic microangiopathies using the trajectory of biomarkers. Nephrol Dial Transplant. 2020;35(9):1538–1546. doi:10.1093/ndt/gfz025
   PubMed Web of Science ®Google Scholar
• George JN, Nester CM, McIntosh JJ. Syndromes of thrombotic microangiopathy associated with pregnancy. Hematol Am Soc Hematol Educ Prog. 2015;2015:644–648. doi:10.1182/asheducation-2015.1.644
   PubMedGoogle Scholar
• Fakhouri F, Scully M, Ardissino G, Al-Dakkak I, Miller B, Rondeau E. Pregnancy-triggered atypical hemolytic uremic syndrome (aHUS): a Global aHUS Registry analysis. J Nephrol. 2021;34(5):1581–1590. doi:10.1007/s40620-021-01025-x
   PubMed Web of Science ®Google Scholar
• Huerta A, Arjona E, Portoles J, et al. A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome. Kidney Int. 2018;93(2):450–459. doi:10.1016/j.kint.2017.06.022
   PubMed Web of Science ®Google Scholar
• Loeven MA, Rops AL, Lehtinen MJ, et al. Mutations in complement factor h impair alternative pathway regulation on mouse glomerular endothelial cells in vitro. J Biol Chem. 2016;291(10):4974–4981. doi:10.1074/jbc.M115.702506
   PubMed Web of Science ®Google Scholar
• Larakeb A, Leroy S, Frémeaux-Bacchi V, et al. Ocular involvement in hemolytic uremic syndrome due to factor H deficiency--are there therapeutic consequences? Pediatr Nephrol. 2007;22(11):1967–1970. doi:10.1007/s00467-007-0540-0
   PubMed Web of Science ®Google Scholar
• Zheng X, Gorovoy IR, Mao J, Jin J, Chen X, Cui QN. Recurrent ocular involvement in pediatric atypical hemolytic uremic syndrome. J Pediatr Ophthalmol Strabismus. 2014;51:e62–e65. doi:10.3928/01913913-20140923-03
   Web of Science ®Google Scholar
• Greenwood GT. Case report of atypical hemolytic uremic syndrome with retinal arterial and venous occlusion treated with eculizumab. Int Med Case Rep J. 2015;8:235–239. doi:10.2147/IMCRJ.S90640
   PubMed Web of Science ®Google Scholar
• David R, Hochberg-Klein S, Amer R. Resolution of ocular involvement with systemic eculizumab therapy in atypical hemolytic-uremic syndrome. Eye. 2013;27(8):997–998. doi:10.1038/eye.2013.111
   PubMed Web of Science ®Google Scholar
• Loo CY, Mohamed Said MS, Mohd R, et al. Immunoadsorption and plasmapheresis are equally efficacious as adjunctive therapies for severe lupus nephritis. Transfus Apher Sci. 2010;43(3):335–340. doi:10.1016/j.transci.2010.10.003
   PubMed Web of Science ®Google Scholar
• Koziolek MJ, Tampe D, Bähr M, et al. Immunoadsorption therapy in patients with multiple sclerosis with steroid-refractory optical neuritis. J Neuroinflammation. 2012;9:80. doi:10.1186/1742-2094-9-80
   PubMed Web of Science ®Google Scholar
• Kavanagh D, Goodship TH, Richards A. Atypical hemolytic uremic syndrome. Semin Nephrol. 2013;33(6):508–530. doi:10.1016/j.semnephrol.2013.08.003
   PubMed Web of Science ®Google Scholar
• Bresin E, Rurali E, Caprioli J, et al; European Working Party on Complement Genetics in Renal Diseases. Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol. 2013;24(3):475–486. doi:10.1681/ASN.2012090884
   PubMed Web of Science ®Google Scholar
• Khandelwal P, Thomas CC, Rathi BS, et al. Membrane-filtration based plasma exchanges for atypical hemolytic uremic syndrome: audit of efficacy and safety. J Clin Apher. 2019;34(5):555–562. doi:10.1002/jca.21711
   PubMed Web of Science ®Google Scholar
• Lee H, Kang E, Kang HG, et al. Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome. Korean J Intern Med. 2020;35(1):25–40. doi:10.3904/kjim.2019.388
   PubMed Web of Science ®Google Scholar
• Fakhouri F, Fila M, Hummel A, et al. Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study. Blood. 2021;137(18):2438–2449. doi:10.1182/blood.2020009280
   PubMed Web of Science ®Google Scholar
• Cheong HI, Jo SK, Yoon SS, et al. Clinical practice guidelines for the management of atypical hemolytic uremic syndrome in Korea. J Korean Med Sci. 2016;31(10):1516–1528. doi:10.3346/jkms.2016.31.10.1516
   PubMed Web of Science ®Google Scholar
• Licht C, Greenbaum LA, Muus P, et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of Phase 2 studies. Kidney Int. 2015;87(5):1061–1073. doi:10.1038/ki.2014.423
   PubMed Web of Science ®Google Scholar
• Fakhouri F, Hourmant M, Campistol JM, et al. Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial. Am J Kidney Dis. 2016;68(1):84–93. doi:10.1053/j.ajkd.2015.12.034
   PubMed Web of Science ®Google Scholar
• Cavero T, Rabasco C, López A, et al. Eculizumab in secondary atypical haemolytic uraemic syndrome. Nephrol Dial Transplant. 2017;32(3):466–474. doi:10.1093/ndt/gfw453
   PubMed Web of Science ®Google Scholar
• Menne J, Delmas Y, Fakhouri F, et al. Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study. BMC Nephrol. 2019;20(1):125. doi:10.1186/s12882-019-1314-1
   PubMedGoogle Scholar
• Dixon BP, Madris-Aris AD, Adams B. Two-year efficacy and safety of ravulizumab in adults and children with Atypical Hemolytic Uremic Syndrome (aHUS): analysis of two phase 3 studies. Blood. 2021;138(1):769. doi:10.1182/blood-2021-145040
   Google Scholar
• Kulasekararaj AG, Hill A, Rottinghaus ST, et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. Blood. 2019;133(6):540–549. doi:10.1182/blood-2018-09-876805
   PubMed Web of Science ®Google Scholar
• Sheridan D, Yu ZX, Zhang Y, et al. Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action. PLoS One. 2018;13(4):e0195909. doi:10.1371/journal.pone.0195909
   PubMed Web of Science ®Google Scholar
• Zuber J, Le Quintrec M, Krid S, et al.; French Study Group for Atypical HUS. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant. 2012;12(12):3337–3354. doi:10.1111/j.1600-6143.2012.04252.x
   PubMed Web of Science ®Google Scholar
• Portoles J. Characteristics, management and outcomes of atypical haemolytic uraemic syndrome in kidney transplant patients: a retrospective national study. Clin Kidney J. 2021;14(4):1173–1180. doi:10.1093/ckj/sfaa096
   PubMed Web of Science ®Google Scholar
• Durey MA, Sinha A, Togarsimalemath SK, Bagga A. Anti-complement-factor H-associated glomerulopathies. Nat Rev Nephrol. 2016;12(9):563–578. doi:10.1038/nrneph.2016.99
   PubMed Web of Science ®Google Scholar
• Boyer O, Balzamo E, Charbit M, et al. Pulse cyclophosphamide therapy and clinical remission in atypical hemolytic uremic syndrome with anti-complement factor H autoantibodies. Am J Kidney Dis. 2010;55(5):923–927. doi:10.1053/j.ajkd.2009.12.026
   PubMed Web of Science ®Google Scholar
• Raina R, Chauvin A, Fox K, et al. Effect of immunosuppressive therapy on the occurrence of atypical hemolytic uremic syndrome in renal transplant recipients. Ann Transplant. 2018;23:631–638. doi:10.12659/AOT.909781
   PubMed Web of Science ®Google Scholar
• Law SK. First-line treatment for elevated intraocular pressure (IOP) associated with open-angle glaucoma or ocular hypertension: focus on bimatoprost. Clin Ophthalmol. 2007;1(3):225–232.
   PubMedGoogle Scholar
• Fakhouri F, Schwotzer N, Frémeaux-Bacchi V. How I diagnose and treat atypical hemolytic uremic syndrome. Blood. 2023;141(9):984–995. doi:10.1182/blood.2022017860
   PubMed Web of Science ®Google Scholar
• Raina R, Grewal MK, Radhakrishnan Y, et al. Optimal management of atypical hemolytic uremic disease: challenges and solutions. Int J Nephrol Renovasc Dis. 2019;12:183–204. doi:10.2147/IJNRD.S215370
   PubMed Web of Science ®Google Scholar
• Ritter C. Dr. Anuja Java Co-chairs Working Group in an International Committee for Revising Ahus Nomenclature; 2021. Division of Nephrology. Available from: https://nephrology.wustl.edu/dr-anuja-java-co-chairs-working-group-for-revising-ahus-nomenclature/. Accessed July 31, 2023.
   Google Scholar
• Muir E. The rare reality - an insight into the patient and family experience of rare disease: report launch. Rare Disease UK; 2016. Available from: https://www.raredisease.org.uk/rduk-news/the-rare-reality-an-insight-into-The-patient-and-family-experience-of-rare-disease-report-launch/. Accessed July 31, 2023.
   Google Scholar
• Marsden S, Dunbar L, Sandiford N. Do multidisciplinary teams make a difference to the quality of medical care? Br J Hosp Med. 2019;80(12):696–698. doi:10.12968/hmed.2019.80.12.696
   Web of Science ®Google Scholar
• Uriol Rivera MG, Cabello Pelegrin S, Ballester Ruiz C, et al. Impact of a multidisciplinary team for the management of thrombotic microangiopathy. PLoS One. 2018;13(11):e0206558. doi:10.1371/journal.pone.0206558
   PubMed Web of Science ®Google Scholar
• Azoulay E, Knoebl P, Garnacho-Montero J, et al. Expert statements on the standard of care in critically ill adult patients with atypical hemolytic uremic syndrome. Chest. 2017;152(2):424–434. doi:10.1016/j.chest.2017.03.055
   PubMed Web of Science ®Google Scholar